These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 19141032)
1. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Takai H; Kato A; Kato C; Watanabe T; Matsubara K; Suzuki M; Kataoka H Liver Int; 2009 Aug; 29(7):1056-64. PubMed ID: 19141032 [TBL] [Abstract][Full Text] [Related]
2. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368 [TBL] [Abstract][Full Text] [Related]
3. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma. Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714 [TBL] [Abstract][Full Text] [Related]
4. [Relationship between glypican-3 and Notch1 expressions in hepatocellular carcinoma]. Peng F; Wu Z; Li X Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):590-2, 597. PubMed ID: 23644127 [TBL] [Abstract][Full Text] [Related]
5. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806 [TBL] [Abstract][Full Text] [Related]
6. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells]. Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080 [TBL] [Abstract][Full Text] [Related]
7. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409 [TBL] [Abstract][Full Text] [Related]
8. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis. Pan Z; Chen C; Long H; Lei C; Tang G; Li L; Feng J; Chen F Mol Med Rep; 2013 Mar; 7(3):969-74. PubMed ID: 23338845 [TBL] [Abstract][Full Text] [Related]
11. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925 [TBL] [Abstract][Full Text] [Related]
12. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665 [TBL] [Abstract][Full Text] [Related]
14. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053 [TBL] [Abstract][Full Text] [Related]
15. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice. Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124 [TBL] [Abstract][Full Text] [Related]
16. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma]. DU JL; Wei LX; Wang YL Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352 [TBL] [Abstract][Full Text] [Related]
17. Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. Takai H; Ashihara M; Ishiguro T; Terashima H; Watanabe T; Kato A; Suzuki M Cancer Biol Ther; 2009 Dec; 8(24):2329-38. PubMed ID: 19838081 [TBL] [Abstract][Full Text] [Related]
18. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037 [TBL] [Abstract][Full Text] [Related]
20. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients. Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]